Literature DB >> 14594904

Thrombolysis: newer thrombolytic agents and their role in clinical medicine.

T K Nordt1, C Bode.   

Abstract

Mesh：

Substances：

Year:  2003        PMID： 14594904      PMCID： PMC1767956          DOI： 10.1136/heart.89.11.1358

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  13 in total

1.  TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators.

Authors:  C P Cannon; C M Gibson; C H McCabe; A A Adgey; M J Schweiger; R F Sequeira; G Grollier; R P Giugliano; M Frey; H S Mueller; R M Steingart; W D Weaver; F Van de Werf; E Braunwald
Journal:  Circulation       Date:  1998 Dec 22-29       Impact factor: 29.690

2.  Augmented platelet aggregation as predictor of reocclusion after thrombolysis in acute myocardial infarction.

Authors:  T K Nordt; M Moser; B Kohler; J Ruef; K Peter; W Kübler; C Bode
Journal:  Thromb Haemost       Date:  1998-12       Impact factor: 5.249

3.  Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial.

Authors:  J A de Lemos; E M Antman; C M Gibson; C H McCabe; R P Giugliano; S A Murphy; S A Coulter; K Anderson; J Scherer; M J Frey; R Van Der Wieken; F Van De Werf; E Braunwald
Journal:  Circulation       Date:  2000-01-25       Impact factor: 29.690

4.  Intravenous NPA for the treatment of infarcting myocardium early; InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction.

Authors: 
Journal:  Eur Heart J       Date:  2000-12       Impact factor: 29.983

5.  Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group.

Authors: 
Journal:  Circulation       Date:  2000-06-20       Impact factor: 29.690

6.  Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.

Authors:  E J Topol
Journal:  Lancet       Date:  2001-06-16       Impact factor: 79.321

7.  Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial.

Authors:  F Van De Werf; J Adgey; D Ardissino; P W Armstrong; P Aylward; G Barbash; A Betriu; A S Binbrek; R Califf; R Diaz; R Fanebust; K Fox; C Granger; J Heikkilä; S Husted; P Jansky; A Langer; E Lupi; A Maseri; J Meyer; J Mlczoch; D Mocceti; D Myburgh; A Oto; E Paolasso; K Pehrsson; R Seabra-Gomes; L Soares-Piegas; D Sùgrue; M Tendera; E Topol; P Toutouzas; A Vahanian; F Verheugt; L Wallentin; H White
Journal:  Lancet       Date:  1999-08-28       Impact factor: 79.321

8.  Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.

Authors: 
Journal:  Lancet       Date:  2001-08-25       Impact factor: 79.321

Review 9.  Pharmacokinetics and pharmacodynamics of lanoteplase (n-PA).

Authors:  T K Nordt; M Moser; B Kohler; W Kübler; C Bode
Journal:  Thromb Haemost       Date:  1999-09       Impact factor: 5.249

10.  Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction: a double-blind, randomized angiographic trial of lanoteplase versus alteplase.

Authors:  P den Heijer; F Vermeer; E Ambrosioni; Z Sadowski; J L López-Sendón; R von Essen; P Beaufils; U Thadani; J Adgey; L Pierard; J Brinker; R F Davies; R W Smalling; L Wallentin; A Caspi; A Pangerl; L Trickett; C Hauck; D Henry; P Chew
Journal:  Circulation       Date:  1998-11-17       Impact factor: 29.690
View more
  19 in total

Review 1.  Paramedics and pre-hospital management of acute myocardial infarction: diagnosis and reperfusion.

Authors:  S Johnston; R Brightwell; M Ziman
Journal:  Emerg Med J       Date:  2006-05       Impact factor: 2.740

Review 2.  Translational initiatives in thrombolytic therapy.

Authors:  Melvin E Klegerman
Journal:  Front Med       Date:  2017-03-02       Impact factor: 4.592

3.  Purification of serine protease from polychaeta, Lumbrineris nipponica, and assessment of its fibrinolytic activity.

Authors:  Seung Ju Yeon; Goo Yong Chung; Jae Sang Hong; Jin Ha Hwang; Hwa Sung Shin
Journal:  In Vitro Cell Dev Biol Anim       Date:  2017-03-10       Impact factor: 2.416

4.  Expression of the truncated tissue plasminogen activator (K2S) gene in tobacco chloroplast.

Authors:  Maryam Abdoli-Nasab; Mokhtar Jalali-Javaran; Rosa M Cusidó; Javier Palazón; Amin Baghizadeh; Houshang Alizadeh
Journal:  Mol Biol Rep       Date:  2013-10-11       Impact factor: 2.316

5.  Expression of a novel chimeric-truncated tPA in Pichia pastoris with improved biochemical properties.

Authors:  Amirhossein Saadatirad; Soroush Sardari; Mohammadreza Kazemali; Najmeh Zarei; Fatemeh Davami; Farzaneh Barkhordari; Ahmad Adeli; Fereidoun Mahboudi
Journal:  Mol Biotechnol       Date:  2014-12       Impact factor: 2.695

Review 6.  Advanced drug delivery systems for antithrombotic agents.

Authors:  Colin F Greineder; Melissa D Howard; Ronald Carnemolla; Douglas B Cines; Vladimir R Muzykantov
Journal:  Blood       Date:  2013-06-24       Impact factor: 22.113

7.  Expression of active recombinant human tissue-type plasminogen activator by using in vivo polyhydroxybutyrate granule display.

Authors:  Yanping Geng; Shengjun Wang; Qingsheng Qi
Journal:  Appl Environ Microbiol       Date:  2010-09-10       Impact factor: 4.792

8.  Rational design of a new variant of Reteplase with optimized physicochemical profile and large-scale production in Escherichia coli.

Authors:  Hooria Seyedhosseini Ghaheh; Shabnam Sajjadi; Fatemeh Shafiee; Ebrahim Barzegari; Fatemeh Moazen; Hamid Mir Mohammad Sadeghi
Journal:  World J Microbiol Biotechnol       Date:  2022-01-06       Impact factor: 3.312

9.  Asn and asn: critical residues for in vitro biological activity of reteplase.

Authors:  Naganath Mandi; Kalyana R Sundaram; Sunil K Tandra; Suman Bandyopadhyay; Sriram Padmanabhan
Journal:  Adv Hematol       Date:  2010-06-21

Review 10.  Delivery of drugs bound to erythrocytes: new avenues for an old intravascular carrier.

Authors:  Carlos H Villa; Daniel C Pan; Sergei Zaitsev; Douglas B Cines; Donald L Siegel; Vladimir R Muzykantov
Journal:  Ther Deliv       Date:  2015-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.